Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 188.13B |
| Revenue (ttm) | 47.05B |
| Net Income (ttm) | 11.37B |
| Shares Out | 1.96B |
| EPS (ttm) | 5.64 |
| PE Ratio | 17.03 |
| Forward PE | 14.17 |
| Dividend | 3.50 (3.65%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 2,024,020 |
| Average Volume | 3,382,543 |
| Open | 96.28 |
| Previous Close | 96.02 |
| Day's Range | 95.94 - 97.23 |
| 52-Week Range | 81.10 - 102.72 |
| Beta | 0.53 |
| RSI | 56.75 |
| Earnings Date | Jul 17, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Final Trades: Novartis, Sixth Street, Amazon and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Novartis, Sixth Street, Amazon and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Novartis in deal with ProFound for cardiovascular disease therapies
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen Inc. (NASDAQ: BIIB) on Wednesday announced in a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for ...
Novartis completes acquisition of Regulus Therapeutics
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common st...
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.
Novartis: A SWAN Worth Owning
Novartis AG offers growth potential with a balanced drug portfolio, manageable debt, and shares priced below fair value. Click for my updated look at NVS stock.
Novartis announces expiration of Regulus Therapeutics tender offer
Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of N...
Divi’s Laboratories shares in focus after Novartis and MSN settle on Entresto 659 patent
Shares of Divi’s Laboratories are in focus after an update in the legal proceedings surrounding Novartis’ heart failure drug Entresto. Novartis and MSN Laboratories have reached a settlement on the ‘6...
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis AG NVS on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with paroxysma...
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patien...
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co . (NYSE: BMY) entered into a co-development and co-commercialization agreement . The pact focuses on BioNTech’s investigational bispecific an...
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a ...
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormon...
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
The U.S. Food and Drug Administration (FDA) on Wednesday approved Alcon Plc’s (NYSE: ALC) Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for signs and symptoms of Dry Ey...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to a...
If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)
I've added Novo Nordisk and Novartis to boost The Dividend Income Accelerator's healthcare allocation and global diversification, reducing overall risk and volatility. Both companies are attractively ...
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncol...
Incyte and Novartis settle royalties dispute related to Jakafi
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion
GSK plc (NYSE: GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa . Under the agreement, GSK will pay up to $2 billion in total cash consideration. This include...
Greece needs urgent cardiovascular disease action plan, says leading health executive
Greek use of interoperable digital tools and secure data platforms such as the EHDS could boost early detection and personalised treatment, while advancing CVD care, a senior Novartis executive tells ...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...